| Published Application/Species/Sample/Dilution | Reference |
|---|
- blocking or activating experiments; mouse; ; fig 6f
| Uyanik B, Goloudina A, Akbarali A, Grigorash B, Petukhov A, Singhal S, et al. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. Nat Commun. 2021;12:3622 pubmed publisher |
- blocking or activating experiments; mouse; ; fig s2a
| Totten S, Im Y, Cepeda Cañedo E, Najyb O, Nguyen A, Hebert S, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021;12:3299 pubmed publisher |
| Baraibar I, Roman M, Rodriguez Remirez M, Lopez I, Vilalta A, Guruceaga E, et al. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. Cancers (Basel). 2020;12: pubmed publisher |
| Zhou T, Damsky W, Weizman O, McGeary M, Hartmann K, Rosen C, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583:609-614 pubmed publisher |
| Waaler J, Mygland L, Tveita A, Strand M, Solberg N, Olsen P, et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models. Commun Biol. 2020;3:196 pubmed publisher |
| Santana Magal N, Farhat Younis L, Gutwillig A, Gleiberman A, Rasoulouniriana D, Tal L, et al. Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. Cancer Res. 2020;80:1942-1956 pubmed publisher |
| Li Y, Zhang M, Wang X, Liu W, Wang H, Yang Y. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. Nat Commun. 2020;11:581 pubmed publisher |
| Sun G, Cao Y, Qian C, Wan Z, Zhu J, Guo J, et al. Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages. Aging (Albany NY). 2020;12:1114-1127 pubmed publisher |
| Zhong W, Myers J, Wang F, Wang K, Lucas J, Rosfjord E, et al. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics. 2020;21:2 pubmed publisher |
| Krotova K, Day A, Aslanidi G. An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation. Mol Ther Oncolytics. 2019;15:166-177 pubmed publisher |
| Panigrahy D, Gartung A, Yang J, Yang H, Gilligan M, Sulciner M, et al. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J Clin Invest. 2019;129:2964-2979 pubmed publisher |
| Konen J, Rodriguez B, Fradette J, Gibson L, Davis D, Minelli R, et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel). 2019;11: pubmed publisher |
| Hammerich L, Marron T, Upadhyay R, Svensson Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25:814-824 pubmed publisher |
| Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35:559-572.e7 pubmed publisher |
| Blair A, Kleponis J, Thomas D, Muth S, Murphy A, Kim V, et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J Clin Invest. 2019;129:1742-1755 pubmed publisher |
| Shields B, Koss B, Taylor E, Storey A, West K, Byrum S, et al. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019;79:1113-1123 pubmed publisher |
| Liu C, He H, Li X, Su M, Cao Y. Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Br J Cancer. 2019;120:346-355 pubmed publisher |
| Kaplanov I, Carmi Y, Kornetsky R, Shemesh A, Shurin G, Shurin M, et al. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc Natl Acad Sci U S A. 2019;116:1361-1369 pubmed publisher |
| Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, et al. Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nat Commun. 2018;9:5193 pubmed publisher |
| Sato Y, Bolzenius J, Eteleeb A, Su X, Maher C, Sehn J, et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3: pubmed publisher |
| Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher |
| van Montfoort N, Borst L, Korrer M, Sluijter M, Marijt K, Santegoets S, et al. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell. 2018;175:1744-1755.e15 pubmed publisher |
| Sato Kaneko F, Wang X, Yao S, Hosoya T, Lao F, Messer K, et al. Discovery of a Novel Microtubule Targeting Agent as an Adjuvant for Cancer Immunotherapy. Biomed Res Int. 2018;2018:8091283 pubmed publisher |
| Grasselly C, Denis M, Bourguignon A, Talhi N, Mathé D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100 pubmed publisher |
| Vuckovic S, Minnie S, Smith D, Gartlan K, Watkins T, Markey K, et al. Bone marrow transplantation generates T cell-dependent control of myeloma in mice. J Clin Invest. 2019;129:106-121 pubmed publisher |
| Leung C, Yang K, Li X, Chan V, Ku M, Waldmann H, et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Med. 2018;10:71 pubmed publisher |
| Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128:5137-5149 pubmed publisher |
| Dorta Estremera S, Chin R, Sierra G, Nicholas C, Yanamandra A, Nookala S, et al. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Res. 2018;78:5327-5339 pubmed publisher |
| Ghaffari A, Peterson N, Khalaj K, Vitkin N, Robinson A, Francis J, et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br J Cancer. 2018;119:440-449 pubmed publisher |
| Triplett T, Garrison K, Marshall N, Donkor M, Blazeck J, Lamb C, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36:758-764 pubmed publisher |
| Choi J, Beaino W, Fecek R, Fabian K, Laymon C, Kurland B, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med. 2018;59:1843-1849 pubmed publisher |
| Li J, Byrne K, Yan F, Yamazoe T, Chen Z, Baslan T, et al. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity. 2018;49:178-193.e7 pubmed publisher |
| Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37:4941-4954 pubmed publisher |
| Li X, Das I, Lepletier A, Addala V, Bald T, Stannard K, et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018;128:2613-2625 pubmed publisher |
| Crosby E, Wei J, Yang X, Lei G, Wang T, Liu C, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7:e1421891 pubmed publisher |
| Anker J, Naseem A, Mok H, Schaeffer A, Abdulkadir S, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591 pubmed publisher |
| Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115:E4041-E4050 pubmed publisher |
| Bohineust A, Garcia Z, Beuneu H, Lemaitre F, Bousso P. Termination of T cell priming relies on a phase of unresponsiveness promoting disengagement from APCs and T cell division. J Exp Med. 2018;215:1481-1492 pubmed publisher |
| Tamosiuniene R, Manouvakhova O, Mésange P, Saito T, Qian J, Sanyal M, et al. Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension. Circ Res. 2018;122:1689-1702 pubmed publisher |
| Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, et al. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene. 2018;37:3151-3165 pubmed publisher |
| Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher |
| Taggart D, Andreou T, Scott K, Williams J, Rippaus N, Brownlie R, et al. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc Natl Acad Sci U S A. 2018;115:E1540-E1549 pubmed publisher |
| Tang H, Liang Y, Anders R, Taube J, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588 pubmed publisher |
| Tavazoie M, Pollack I, Tanqueco R, Ostendorf B, Reis B, Gonsalves F, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018;172:825-840.e18 pubmed publisher |
| Roussey J, Viglianti S, Teitz Tennenbaum S, Olszewski M, Osterholzer J. Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice. J Immunol. 2017;199:3535-3546 pubmed publisher |
| Huffaker T, Lee S, Tang W, Wallace J, Alexander M, Runtsch M, et al. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem. 2017;292:18530-18541 pubmed publisher |
| Grinberg Bleyer Y, Oh H, Desrichard A, Bhatt D, Caron R, Chan T, et al. NF-?B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 2017;170:1096-1108.e13 pubmed publisher |
| Bucsek M, Qiao G, MacDonald C, Giridharan T, Evans L, Niedzwecki B, et al. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res. 2017;77:5639-5651 pubmed publisher |
| Trsan T, Vuković K, Filipović P, Brizić A, Lemmermann N, Schober K, et al. Cytomegalovirus vector expressing RAE-1? induces enhanced anti-tumor capacity of murine CD8+ T cells. Eur J Immunol. 2017;47:1354-1367 pubmed publisher |
| Kwan B, Zhu E, Tzeng A, Sugito H, Eltahir A, Ma B, et al. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med. 2017;214:1679-1690 pubmed publisher |
| Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544:250-254 pubmed publisher |
| Bartee M, Dunlap K, Bartee E. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res. 2017;77:2952-2963 pubmed publisher |
| Beavis P, Henderson M, Giuffrida L, Mills J, Sek K, Cross R, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127:929-941 pubmed publisher |
| Spitzer M, Carmi Y, Reticker Flynn N, Kwek S, Madhireddy D, Martins M, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15 pubmed publisher |
| Moynihan K, Opel C, Szeto G, Tzeng A, Zhu E, Engreitz J, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402-1410 pubmed publisher |
| Zelenay S, van der Veen A, Böttcher J, Snelgrove K, Rogers N, Acton S, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell. 2015;162:1257-70 pubmed publisher |
| Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher |
| Zander R, Obeng Adjei N, Guthmiller J, Kulu D, Li J, Ongoiba A, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17:628-41 pubmed publisher |
| Vanpouille Box C, Diamond J, Pilones K, Zavadil J, Babb J, Formenti S, et al. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res. 2015;75:2232-42 pubmed publisher |
| Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher |
| Evans E, Jonason A, Bussler H, Torno S, Veeraraghavan J, Reilly C, et al. Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunol Res. 2015;3:689-701 pubmed publisher |
| Mittal D, Young A, Stannard K, Yong M, Teng M, Allard B, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74:3652-8 pubmed publisher |
| McGray A, Hallett R, Bernard D, Swift S, Zhu Z, Teoderascu F, et al. Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther. 2014;22:206-18 pubmed publisher |
| John L, Devaud C, Duong C, Yong C, Beavis P, Haynes N, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636-46 pubmed publisher |
| Holmgaard R, Zamarin D, Munn D, Wolchok J, Allison J. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389-402 pubmed publisher |
| Van Der Werf N, Redpath S, Azuma M, Yagita H, Taylor M. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog. 2013;9:e1003215 pubmed publisher |
| Curran M, Montalvo W, Yagita H, Allison J. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275-80 pubmed publisher |
